ensifentrine (Ohtuvayre)
Jump to navigation
Jump to search
Indications
- maintenance treatment of COPD (FDA-approved 2024)
Contraindications
- caution in patients with depression or suicidal ideation
Dosage
- delivered by nebulizer
Mechanism of action
More general terms
References
- ↑ Anzueto A, Barjaktarevic IZ, Siler TM et al Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo- controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37364283 PMCID: PMC10449067 Free PMC article
- ↑ Donohue JF et al. Ensifentrine as a novel, inhaled treatment for patients with COPD. Int J Chron Obstruct Pulmon Dis 2023 Jul 28; 18:1611 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37533771 PMCID: PMC10392818 Free PMC article. Review. https://www.dovepress.com/ensifentrine-as-a-novel-inhaled-treatment-for-patients-with-copd-peer-reviewed-fulltext-article-COPD
- ↑ U.S. Food and Drug Administration. Prescribing information for Ohtuvayre. FDA 2024 Jun 26; [e-pub]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217389s000lbl.pdf